Andean Precious Metals (CVE:APM) Rating Increased to Moderate Buy at Desjardins

Desjardins upgraded shares of Andean Precious Metals (CVE:APM - Free Report) to a moderate buy rating in a report published on Thursday, Zacks.com reports.

Andean Precious Metals Stock Performance

CVE:APM traded down C$0.13 during trading hours on Thursday, hitting C$1.65. The stock had a trading volume of 316,032 shares, compared to its average volume of 165,066. Andean Precious Metals has a one year low of C$0.55 and a one year high of C$2.18. The stock has a market cap of C$246.44 million, a P/E ratio of 4.34 and a beta of 1.22. The firm has a 50 day moving average price of C$1.43.

Andean Precious Metals (CVE:APM - Get Free Report) last issued its earnings results on Tuesday, August 13th. The company reported C$0.08 EPS for the quarter, meeting the consensus estimate of C$0.08. Andean Precious Metals had a net margin of 23.75% and a return on equity of 41.08%. The firm had revenue of C$95.47 million during the quarter. As a group, sell-side analysts expect that Andean Precious Metals will post 0.3806452 EPS for the current fiscal year.

Insider Buying and Selling at Andean Precious Metals

In other news, insider 2176423 Ontario Ltd. bought 204,600 shares of the stock in a transaction on Monday, September 16th. The stock was purchased at an average price of C$1.14 per share, with a total value of C$233,141.70. Over the last 90 days, insiders bought 1,202,800 shares of company stock valued at $1,607,032. Corporate insiders own 69.37% of the company's stock.

Andean Precious Metals Company Profile

Aptorum Group Limited, a pharmaceutical company, engages in the discovery, development, and commercialization of therapeutic products for the treatment of diseases with a focus on infectious diseases and cancers. Its pipeline enables the discovery of new therapeutics assets, such as systematic screening of existing approved drug molecules, and microbiome-based research platform for treatments of metabolic diseases.